BioSpace News Archive

Advocare, a physician-owned multi-specialty group with nearly 600 providers, continues to expand its footprint in New Jersey and Pennsylvania by welcoming five new independent physician practices into the organization.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following a recent change to the Food and Drug Administration’s (FDA) policy towards the coronavirus outbreak, the Company’s coronavirus test kits are available to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) for use according to the FDA guidelines.

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the presentation of new data from its ongoing HIV research programs at the Conference on Retroviruses and Opportunistic Infections (CROI 2020) taking place March 8 – 11, 2020 in Boston, Massachusetts.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor conferences during March.

Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash.

Applied DNA Expected to Enter Large-Scale Production of Candidates in March; Preclinical Testing in Animals by Takis Biotech Anticipated to Begin in Calendar Q2 2020

First presentation of findings from EPI03, EPI04 and EPI07 studies that examine the pharmacokinetics and pharmacodynamics of single and repeat administration of epinephrine after intranasal, intramuscular and subcutaneous administration

Vizient, Inc. recently shared insights on chimeric antigen receptor T-cell data and its implications for patients with cytokine release syndrome, large B-cell cancer, and pediatric and young adult patients with leukemia.